Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT00105300
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
DRUG:
Adalimumab
Sponsor
Abbott